Hypertension in Patients Treated With Ibrutinib for Chronic Lymphocytic Leukemia | Allergy and Clinical Immunology | JAMA Network Open | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
Coutre  SE, Byrd  JC, Hillmen  P,  et al.  Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.  Blood Adv. 2019;3(12):1799-1807. doi:10.1182/bloodadvances.2018028761PubMedGoogle ScholarCrossref
Jones  J, George  B, Peterson  CB,  et al.  Long-term effects of ibrutinib on blood pressure in patients with chronic lymphocytic leukemia (CLL).  J Clin Oncol. 2019;37(15)(suppl):e19009. doi:10.1200/JCO.2019.37.15_suppl.e19009Google Scholar
Caldeira  D, Alves  D, Costa  J, Ferreira  JJ, Pinto  FJ.  Ibrutinib increases the risk of hypertension and atrial fibrillation: systematic review and meta-analysis.  PLoS One. 2019;14(2):e0211228. doi:10.1371/journal.pone.0211228PubMedGoogle Scholar
Mahida  H, Gharia  B, Ugoeke  N, Maludum  O, Asif  A, Calderon  D.  Evaluation of cardiovascular adverse events associated with ibrutinib, venetoclax and idelalisib used in treatment of chronic lymphocytic leukemia.  Circulation. 2018;138(suppl 1):A11835. doi:10.1161/circ.138.suppl_1.11835Google Scholar
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    Research Letter
    December 2, 2019

    Hypertension in Patients Treated With Ibrutinib for Chronic Lymphocytic Leukemia

    Author Affiliations
    • 1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
    • 2Division of Hematology and Oncology, Department of Medicine, Georgetown University Hospital Lombardi Comprehensive Cancer Center, Washington, DC
    • 3Department of Hematology and Oncology, Northwell Health Cancer Institute, New Hyde Park, New York
    • 4Division of Hematology and Oncology, Department of Medicine, University of Alabama, Birmingham
    • 5Cardiovascular Division, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia
    • 6Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
    JAMA Netw Open. 2019;2(12):e1916326. doi:10.1001/jamanetworkopen.2019.16326

    Hypertension is a commonly noted adverse event for patients with chronic lymphocytic leukemia who are treated with ibrutinib in the clinical trial setting (incidence, 18%; grade ≥3 hypertension, 6%).1 In clinical practice settings, patterns of development of and management strategies for hypertension are less well understood. Thus, we aimed to describe patterns of development, management strategies, and long-term vascular consequences of hypertension associated with ibrutinib in the non–clinical trial setting.

    This multicenter cohort study took place at the Memorial Sloan Cancer Center in New York, New York; the Lombardi Cancer Center, Georgetown University Hospital, in Washington, DC; and the Abramson Cancer Center, University of Pennsylvania, in Philadelphia. It included patients treated with 420 mg of ibrutinib daily for at least 6 months outside of clinical trials; patients requiring dose reductions were excluded. Baseline cardiovascular comorbidities and medication regimens, sequential blood pressure (BP) measurements before and after ibrutinib exposure, adjustments to cardiovascular medication regimens, and development of cardiovascular complications were collected. Institutional review boards at all institutions approved the study, and informed consent was not required because of minimal risk to participants. This study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline.